Monoclonal Antibodies and Recombinant Immunoglobulins for the Treatment of Multiple Sclerosis
出版年份 2011 全文链接
标题
Monoclonal Antibodies and Recombinant Immunoglobulins for the Treatment of Multiple Sclerosis
作者
关键词
-
出版物
CNS DRUGS
Volume 26, Issue 1, Pages 11-37
出版商
Springer Nature
发表日期
2011-12-16
DOI
10.2165/11596920-000000000-00000
参考文献
相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。- Natalizumab treatment for multiple sclerosis: updated recommendations for patient selection and monitoring
- (2011) Ludwig Kappos et al. LANCET NEUROLOGY
- Autoimmune disease after alemtuzumab treatment for multiple sclerosis in a multicenter cohort
- (2011) M. Cossburn et al. NEUROLOGY
- Disease activity return during natalizumab treatment interruption in patients with multiple sclerosis
- (2011) P. W. O'Connor et al. NEUROLOGY
- Rituximab for severe myasthenia gravis - experience from five patients
- (2010) C. Lindberg et al. ACTA NEUROLOGICA SCANDINAVICA
- Assessment of JC virus DNA in blood and urine from natalizumab-treated patients
- (2010) Richard A. Rudick et al. ANNALS OF NEUROLOGY
- Anti-JC virus antibodies: Implications for PML Risk Stratification
- (2010) Leonid Gorelik et al. ANNALS OF NEUROLOGY
- Assay design and sample collection can affect anti-John Cunningham virus antibody detection
- (2010) Susan E. Goelz et al. ANNALS OF NEUROLOGY
- Changes in B- and T-Lymphocyte and Chemokine Levels With Rituximab Treatment in Multiple Sclerosis
- (2010) Laura Piccio et al. ARCHIVES OF NEUROLOGY
- Ofatumumab, a human anti-CD20 monoclonal antibody, for treatment of rheumatoid arthritis with an inadequate response to one or more disease-modifying antirheumatic drugs: Results of a randomized, double-blind, placebo-controlled, phase I/II study
- (2010) Mikkel Østergaard et al. ARTHRITIS AND RHEUMATISM
- New Anti-CD20 Monoclonal Antibodies for the Treatment of B-Cell Lymphoid Malignancies
- (2010) Tadeusz Robak et al. BIODRUGS
- HuMab-7D8, a monoclonal antibody directed against the membrane-proximal small loop epitope of CD20 can effectively eliminate CD20low expressing tumor cells that resist rituximab-mediated lysis
- (2010) T. van Meerten et al. HAEMATOLOGICA
- Successful Treatment with Rituximab in a Patient with Stiff-Person Syndrome Complicated by Dysthyroid Ophthalmopathy
- (2010) Nagaaki Katoh et al. INTERNAL MEDICINE
- Stiff-Person Syndrome
- (2010) Eugene A. Bacorro et al. JCR-JOURNAL OF CLINICAL RHEUMATOLOGY
- Rituximab treatment of stiff-person syndrome in a patient with thymoma, diabetes mellitus and autoimmune thyroiditis
- (2010) J.L. Dupond et al. JOURNAL OF CLINICAL NEUROSCIENCE
- Ofatumumab, a Novel Anti-CD20 Monoclonal Antibody for the Treatment of B-Cell Malignancies
- (2010) Bruce D. Cheson JOURNAL OF CLINICAL ONCOLOGY
- Prevalence and stability of antibodies to the BK and JC polyomaviruses: a long-term longitudinal study of Australians
- (2010) A. Antonsson et al. JOURNAL OF GENERAL VIROLOGY
- JCV detection in multiple sclerosis patients treated with natalizumab
- (2010) Saud A. Sadiq et al. JOURNAL OF NEUROLOGY
- The use of rituximab in myasthenia gravis and Lambert-Eaton myasthenic syndrome
- (2010) P. Maddison et al. JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY
- Pediatric Dosing of Rituximab Revisited: Serum Concentrations in Opsoclonus-myoclonus Syndrome
- (2010) Michael R. Pranzatelli et al. JOURNAL OF PEDIATRIC HEMATOLOGY ONCOLOGY
- Daclizumab in active relapsing multiple sclerosis (CHOICE study): a phase 2, randomised, double-blind, placebo-controlled, add-on trial with interferon beta
- (2010) Daniel Wynn et al. LANCET NEUROLOGY
- Immune responses to JC virus in patients with multiple sclerosis treated with natalizumab: a cross-sectional and longitudinal study
- (2010) Samantha Jilek et al. LANCET NEUROLOGY
- The Complex Clinical Picture of Side Effects to Biologicals
- (2010) Oliver V. Hausmann et al. MEDICAL CLINICS OF NORTH AMERICA
- B cell depletion therapy for new-onset opsoclonus-myoclonus
- (2010) Michael R. Pranzatelli et al. MOVEMENT DISORDERS
- Rituximab add-on therapy for breakthrough relapsing multiple sclerosis: A 52-week phase II trial
- (2010) R. T. Naismith et al. NEUROLOGY
- A Placebo-Controlled Trial of Oral Fingolimod in Relapsing Multiple Sclerosis
- (2010) Ludwig Kappos et al. NEW ENGLAND JOURNAL OF MEDICINE
- Oral Fingolimod or Intramuscular Interferon for Relapsing Multiple Sclerosis
- (2010) Jeffrey A. Cohen et al. NEW ENGLAND JOURNAL OF MEDICINE
- Effects of AIN457, a Fully Human Antibody to Interleukin-17A, on Psoriasis, Rheumatoid Arthritis, and Uveitis
- (2010) W. Hueber et al. Science Translational Medicine
- Primary central nervous system lymphoma in a patient treated with natalizumab
- (2009) Andreas Schweikert et al. ANNALS OF NEUROLOGY
- Natalizumab and central nervous system lymphoma: No clear association
- (2009) Carmen Bozic et al. ANNALS OF NEUROLOGY
- Abnormal B-cell cytokine responses a trigger of T-cell-mediated disease in MS?
- (2009) Amit Bar-Or et al. ANNALS OF NEUROLOGY
- Rituximab in patients with primary progressive multiple sclerosis: Results of a randomized double-blind placebo-controlled multicenter trial
- (2009) Kathleen Hawker et al. ANNALS OF NEUROLOGY
- Monozygotic twins with stiff person syndrome and autoimmune thyroiditis: rituximab inefficacy in a double-blind, randomised, placebo controlled crossover study
- (2009) N Venhoff et al. ANNALS OF THE RHEUMATIC DISEASES
- Effect of Anti-CD25 Antibody Daclizumab in the Inhibition of Inflammation and Stabilization of Disease Progression in Multiple Sclerosis
- (2009) Bibiana Bielekova et al. ARCHIVES OF NEUROLOGY
- Generation of Epstein-Barr virus-specific cytotoxic T lymphocytes resistant to the immunosuppressive drug tacrolimus (FK506)
- (2009) B. De Angelis et al. BLOOD
- Effect of Alemtuzumab (CAMPATH 1-H) in patients with inclusion-body myositis
- (2009) M. C. Dalakas et al. BRAIN
- Why did IL-12/IL-23 antibody therapy fail in multiple sclerosis?
- (2009) Erin E Longbrake et al. Expert Review of Neurotherapeutics
- Long-Term Cerebrospinal Fluid and Blood Lymphocyte Dynamics After Rituximab for Pediatric Opsoclonus-Myoclonus
- (2009) Michael R. Pranzatelli et al. JOURNAL OF CLINICAL IMMUNOLOGY
- B-Cell Reconstitution and BAFF After Alemtuzumab (Campath-1H) Treatment of Multiple Sclerosis
- (2009) Sara A. J. Thompson et al. JOURNAL OF CLINICAL IMMUNOLOGY
- Prevalence of Polyomavirus BK and JC Infection and Replication in 400 Healthy Blood Donors
- (2009) Adrian Egli et al. JOURNAL OF INFECTIOUS DISEASES
- α4-Integrin antagonism with natalizumab
- (2009) Olaf Stüve et al. JOURNAL OF NEUROLOGY
- Glatiramer acetate treatment in PPMS: Why males appear to respond favorably
- (2009) Jerry S. Wolinsky et al. JOURNAL OF THE NEUROLOGICAL SCIENCES
- Effect of natalizumab on clinical and radiological disease activity in multiple sclerosis: a retrospective analysis of the Natalizumab Safety and Efficacy in Relapsing-Remitting Multiple Sclerosis (AFFIRM) study
- (2009) Eva Havrdova et al. LANCET NEUROLOGY
- Monoclonal antibody-associated progressive multifocal leucoencephalopathy in patients treated with rituximab, natalizumab, and efalizumab: a Review from the Research on Adverse Drug Events and Reports (RADAR) Project
- (2009) Kenneth R Carson et al. LANCET ONCOLOGY
- Rituximab and progressive multi-focal leukoencephalopathy: the jury is deliberating
- (2009) Kenneth R. Carson et al. LEUKEMIA & LYMPHOMA
- An exploratory dose-escalating study investigating the safety, tolerability, pharmacokinetics and pharmacodynamics of intravenous atacicept in patients with systemic lupus erythematosus
- (2009) C Pena-Rossi et al. LUPUS
- Daclizumab in treatment of multiple sclerosis patients
- (2009) EN Ali et al. Multiple Sclerosis Journal
- Rituximab in the management of refractory myasthenia gravis
- (2009) Nazlee Zebardast et al. MUSCLE & NERVE
- Atacicept bei Multipler Sklerose
- (2009) H.-P. Hartung NERVENARZT
- GLANCE: Results of a phase 2, randomized, double-blind, placebo-controlled study
- (2009) A. D. Goodman et al. NEUROLOGY
- OCULAR TOXOPLASMOSIS DURING NATALIZUMAB TREATMENT
- (2009) C. Zecca et al. NEUROLOGY
- Biology and treatment of primary central nervous system lymphoma
- (2009) Alain P. Algazi et al. Neurotherapeutics
- Asymptomatic Reactivation of JC Virus in Patients Treated with Natalizumab
- (2009) NEW ENGLAND JOURNAL OF MEDICINE
- Asymptomatic Reactivation of JC Virus in Patients Treated with Natalizumab
- (2009) Yiping Chen et al. NEW ENGLAND JOURNAL OF MEDICINE
- Seroepidemiology of Human Polyomaviruses
- (2009) Jaime M. Kean et al. PLoS Pathogens
- Rituximab in relapsing-remitting multiple sclerosis: A 72-week, open-label, phase I trial
- (2008) Amit Bar-Or et al. ANNALS OF NEUROLOGY
- Treatment of Neuromyelitis Optica With Rituximab
- (2008) ARCHIVES OF NEUROLOGY
- Decrease in the Numbers of Dendritic Cells and CD4+ T Cells in Cerebral Perivascular Spaces Due to Natalizumab
- (2008) Maria del Pilar Martin ARCHIVES OF NEUROLOGY
- Ocrelizumab, a humanized anti-CD20 monoclonal antibody, in the treatment of patients with rheumatoid arthritis: A phase I/II randomized, blinded, placebo-controlled, dose-ranging study
- (2008) Mark C. Genovese et al. ARTHRITIS AND RHEUMATISM
- First clinical use of ofatumumab, a novel fully human anti-CD20 monoclonal antibody in relapsed or refractory follicular lymphoma: results of a phase 1/2 trial
- (2008) A. Hagenbeek et al. BLOOD
- Antibody Engineering Principles and Applications
- (2008) LiNa Loo et al. CANCER JOURNAL
- Hypersensitivity Reactions to Last Generation Chimeric, Umanized and Human Recombinant Monoclonal Antibodies for Therapeutic Use
- (2008) G. Calogiuri et al. CURRENT PHARMACEUTICAL DESIGN
- A review of the current use of rituximab in autoimmune diseases
- (2008) Hakan M. Gürcan et al. INTERNATIONAL IMMUNOPHARMACOLOGY
- Pharmacokinetics and Biological Activity of Atacicept in Patients With Rheumatoid Arthritis
- (2008) Ivan Nestorov et al. JOURNAL OF CLINICAL PHARMACOLOGY
- Natalizumab alters transcriptional expression profiles of blood cell subpopulations of multiple sclerosis patients
- (2008) Raija L.P. Lindberg et al. JOURNAL OF NEUROIMMUNOLOGY
- Effect of laquinimod on MRI-monitored disease activity in patients with relapsing-remitting multiple sclerosis: a multicentre, randomised, double-blind, placebo-controlled phase IIb study
- (2008) G Comi et al. LANCET
- Efficacy and safety of oral fumarate in patients with relapsing-remitting multiple sclerosis: a multicentre, randomised, double-blind, placebo-controlled phase IIb study
- (2008) Ludwig Kappos et al. LANCET
- Repeated subcutaneous injections of IL12/23 p40 neutralising antibody, ustekinumab, in patients with relapsing-remitting multiple sclerosis: a phase II, double-blind, placebo-controlled, randomised, dose-ranging study
- (2008) Benjamin M Segal et al. LANCET NEUROLOGY
- Alemtuzumab vs. Interferon Beta-1a in Early Multiple Sclerosis
- (2008) NEW ENGLAND JOURNAL OF MEDICINE
- Melanoma Complicating Treatment with Natalizumab for Multiple Sclerosis
- (2008) John T. Mullen et al. NEW ENGLAND JOURNAL OF MEDICINE
- More on Melanoma with Transdifferentiation
- (2008) NEW ENGLAND JOURNAL OF MEDICINE
- B-Cell Depletion with Rituximab in Relapsing–Remitting Multiple Sclerosis
- (2008) Stephen L. Hauser et al. NEW ENGLAND JOURNAL OF MEDICINE
- RESPONSE TO RITUXIMAB AND PREDNISOLONE FOR OPSOCLONUS-MYOCLONUS-ATAXIA SYNDROME IN A CHILD WITH GANGLIONEUROBLASTOMA
- (2008) Funda Corapcioglu et al. PEDIATRIC HEMATOLOGY AND ONCOLOGY
- Rituximab and Intravenous Immunoglobulins for Relapsing Postinfectious Opsoclonus-Myoclonus Syndrome
- (2008) Wilhelmina G. Leen et al. PEDIATRIC NEUROLOGY
- The Biology of Interleukin-2
- (2007) Thomas R. Malek Annual Review of Immunology
- Treatment of neuroblastoma-related opsoclonus–myoclonus–ataxia syndrome with high-dose dexamethasone pulses
- (2007) Florian Ertle et al. PEDIATRIC BLOOD & CANCER
- Rituximab for treatment of opsoclonus-myoclonus syndrome in neuroblastoma
- (2006) Michael J. Burke et al. PEDIATRIC BLOOD & CANCER
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started